KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.

Xinhua LiuRongfang QiuMin XuMiaomiao MengSiyu ZhaoJian-Song JiYang Yang

Published in: Breast cancer research and treatment (2021)

We conclude that KMT2C could serve as a potential biomarker of prognosis and chemotherapy sensitivity by affecting the DNA damage repair-related genes of breast cancer.

Keyphrases

dna damage
locally advanced
dna repair
breast cancer risk